Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Endocrinology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Diabetes Mellitus, Type 2 Clinical Trials

A listing of Diabetes Mellitus, Type 2 medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (71) clinical trials

Dapagliflozin Patient Satisfaction Survey

This is a cross-sectional, observational patient survey study. Study subjects will be adult commercial members of the large US health plan affiliated with Optum with evidence of T2D initiating dapagliflozin or a sulfonylurea medication within the 3 months prior to survey mailing.

Phase N/A

Assessing Progression to Type-2 Diabetes (APT-2D): A Prospective Cohort Study Expanded From BRITE-SPOT (Bio-bank and Registry for StratIfication and Targeted intErventions in the Spectrum Of Type 2 Diabetes)

This is a prospective open cohort study. The study will comprise the following periods: Screening • Complete screening checklist and informed consent form Procedures. - Following the screening visit, subjects are required to return to undergo the following: - Oral Glucose Tolerance Test (OGTT) to assess glucose tolerance and beta ...

Phase N/A

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

To monitor the safety profile and effectiveness of Empagliflozin in Korea patients with type 2 diabetes mellitus in a routine clinical practice setting

Phase N/A

PASS to Assess Risk of Renal Injury Hepatic Injury Diabetic Ketoacidosis and Infections in Empagliflozin-treated Patients

Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic control in adults. As part of the risk management plan, Boehringer Ingelheim International GmbH (BI) has committed ...

Phase N/A

Study With Dapagliflozin

Objectives and Hypotheses: Primary objective: To describe HbA1c (glycosylated haemoglobin) change from baseline to follow-up Secondary objectives: Clinical data: - To estimate percentage (%) of patients with reduction of HbA1c by 0.5% or more from baseline to follow-up - To estimate percentage (%) of patients reaching the therapeutic glycemic response ...

Phase N/A

Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice

The drug being studied in this study is called alogliptin and alogliptin FDCs. Alogliptin and alogliptin FDCs is being researched to treat people who have diabetes mellitus type 2. This study will look at the glycosylated hemoglobin (HbA1c) level dynamics in participants with diabetes mellitus type 2. The study will ...

Phase N/A

Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors

In September 2015 the EMPA-REG trial presented data on positive effects of empagliflozin, a SGLT-2 inhibitor on cardiovascular (CV) outcomes. This has created a need for data on how this class of medicines affect CV event rates when used in clinical practice. The primary aim of this observational study is ...

Phase N/A

PAR Regulation of Platelet Function in Diabetic Patients

Given the known roles of proteases and PARs in coagulation, inflammation, pain, healing and protection, the need for development of a PAR antagonist as a therapeutic agent for treatment of thrombosis, atherosclerosis and inflammation is well-recognized. Thus, blocking PAR action by inhibiting the PAR-G protein interface is an alternative target ...

Phase N/A

Natural History of Autoimmune Diabetes and Its Complications

Individuals with known or suspected autoimmune mediated diabetes, or healthy individuals at risk for developing the disease, will be evaluated at the NIH Clinical Center. Studies will include characterizing the disease s clinical and laboratory features, observing the natural history of the disease and its complications, evaluating responses to standard ...

Phase N/A

Insulin Resistance And End Stage Renal Disease: The Role Of Retinol Binding Protein 4

The purpose of this study is to determine whether Retinol binding protein 4 has a role in insulin resistance development in patients suffering from end stage renal disease on hemodialysis.

Phase N/A